before somebody else steps in to correct me.. I would like to clarify my post - as I have incorrectly merged two data sets in my post, which should be looked at separately.
So to clarify ...
The primary end-point for the phase III trial is response at 28 days which using the expanded access program + phase 2 placebo controlled trial data (in combination) met the primary endpoint with a p-value of 0.0014, that is 99.86% confidence.
The 82% vs 39% result (with p=0.0001) was the 100 day survival rate when comparing responders vs non-responders, which is actually a secondary endpoint in the phase III trial.
before somebody else steps in to correct me.. I would like to...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
0.010(0.61%) |
Mkt cap ! $2.114B | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.64 | $5.790M | 3.482M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 460 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 67181 | 6 |
View Market Depth
| Last trade - 16.10pm 11/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |